IDH1 and astrocytoma (excluding glioblastoma): A first-in-humans, multicenter, single-arm open-label phase I trial (NOA-16, NCT02454634), which included 33 patients with newly diagnosed WHO grade 3 and 4 IDH1(R132H) mutated astrocytoma, demonstrated safety and immunogenicity of IDH1-vac [115].